AHA: Chevron Ruling Could Undermine J&J’s 340B Rebate Model

The American Hospital Association is pressing the Health Resources and Services Administration (HRSA) to slap civil monetary penalties on Johnson & Johnson for shifting to a new rebate model for 340B drugs, and told Inside Health Policy the Supreme Court’s recent decision to ax the Chevron principle hurts rather than helps J&J's stance. The comments come as health industry lawyers have widely speculated the high court’s decision to get rid of its Chevron deference to agencies’ interpretation...